In Brief: Neozyme II/NABI HyperGAM+CF
Executive Summary
Neozyme II/NABI HyperGAM+CF: Phase II trial for the treatment of severe Pseudomonas lung infections in cystic fibrosis patients discontinued after an interim analysis showed no reduction in acute pulmonary exacerbation. Neozyme owner Genzyme, which has marketing rights to NABI's HyperGAM+CF, said at the Alex. Brown analysts conference in May that the product had the potential to exceed the Ceredase/Cerezyme CF line in revenues. Genzyme and NABI had been in negotiations to modify the agreement so that Genzyme could terminate the deal upon receipt of the trial results ("The Pink Sheet" May 27, T&G-5)...